Loading clinical trials...

Multimodal Neuromodulation in Individuals With Parkinson's Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Multimodal Neuromodulation in Individuals With Parkinson's Disease

NCT05105776•Ryan D'Arcy

Summary

Multimodal non-invasive neuromodulation paired with physical therapy is a promising treatment modality for Parkinson's Disease ("PD"), however the optimal stimulation method, dose, and associated therapeutic protocol for long-lasting clinical benefits have not yet been identified for this population. Here the investigators aim to develop and execute a preliminary clinical study exploring the potential benefits of multimodal non-invasive neuromodulation. The therapeutic intervention will involve translingual neurostimulation +/- galvanic neurostimulation, paired with an intensive physical and cognitive therapy program.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A diagnosis of idiopathic PD
•2. Disease staging between II and III (mild to moderate), according to the modified Hoehn and Yahr scale;
•3. Currently taking prescribed antiparkinsonian medication regularly with:
•4. No medication changes in the last 30 days
•5. Responsive to oral dopamine replacement therapy
•6. Score higher than 24, verified through the Montreal Cognitive Assessment33.
•7. Must demonstrate moderate burden of motor symptoms (MDS-UPDRS part II \>12 and MDS-UPDRS part III scores \>35) 34
•8. Must be able to voluntarily give written (or verbal) informed consent
•9. Must have ability to reliably use the devices
•10. Must be able to understand and complete all assessments (provided in English only)

Exclusion Criteria

•11. Diagnosis of atypical parkinsonism;
•12. History of epilepsy
•13. Presence of an implanted electrical device
•14. Previous surgical intervention for PD (DBS implantation - deep brain stimulation);
•15. Treated with a pump for continuous delivery of DRT (Dopamine replacement therapy)
•16. Presence of severe freezing episodes.
•17. Women who are pregnant or nursing
•18. History of unstable mood disorder or unstable anxiety disorder or psychosis
•19. Those with a recent history of substance abuse and/or dependence (alcohol or other drugs)
•20. Have been diagnosed with neurological disease other than Parkinson's disease.
+8 more criteria

Locations (1)

Centre for Neurology Studies

Surrey, British Columbia, Canada

Key Dates

Start Date

February 9, 2022

Primary Completion Date

May 2, 2024

Completion Date

May 2, 2024

Last Updated

May 29, 2024

Enrollment

ACTUAL participants

Conditions

Parkinson Disease

Interventions

Galvanic stimulation

DEVICE

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 29, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multimodal Neuromodulation in Individuals With Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients